Monoclonal Antibody Therapeutics Market Report 2026

The monoclonal antibody therapeutics market size has grown rapidly in recent years. It will grow from $224.62 billion in 2025 to $252.19 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to limited antibody engineering technologies, early adoption in oncology therapeutics, reliance on traditional clinical trial methods, constrained biologics manufacturing capacity, growing awareness of targeted therapies.

The monoclonal antibody therapeutics market size is expected to see rapid growth in the next few years. It will grow to $396.1 billion in 2030 at a compound annual growth rate (CAGR) of 11.9%. The growth in the forecast period can be attributed to advances in bispecific and multi-specific antibodies, increased biologics and fusion protein production, rising autoimmune and infectious disease prevalence, expansion of hospital and private clinic adoption, integration of ai and automation in drug discovery. Major trends in the forecast period include rising investment in monoclonal antibody research and development, expansion of oncology and autoimmune therapeutics, increasing adoption of antibody-drug conjugates, growth in personalized and targeted therapies, enhancement of clinical trial infrastructure and biomanufacturing capabilities.

The rising prevalence of autoimmune diseases is expected to drive growth in the monoclonal antibody therapeutics market in the coming years. Autoimmune diseases are conditions in which the body’s immune system mistakenly attacks its own healthy tissues and organs, perceiving them as foreign threats, resulting in chronic inflammation and tissue damage. The prevalence of these diseases is increasing due to environmental changes, as heightened exposure to pollutants and altered microbial environments can trigger abnormal immune responses in susceptible individuals. Monoclonal antibody therapeutics are effective for autoimmune diseases because they precisely target and block specific immune pathways responsible for inflammation and tissue damage, helping reduce symptoms and slow disease progression. For example, in November 2023, the Multiple Sclerosis International Federation (MSIF), a UK-based international nonprofit organization, reported that an estimated 2.9 million people worldwide were living with multiple sclerosis, a type of autoimmune and immune-mediated disease, in 2023. This indicates that the growing prevalence of autoimmune diseases is fueling the monoclonal antibody therapeutics market.

Key companies in the monoclonal antibody therapeutics market are focusing on innovative solutions, such as bispecific monoclonal antibodies, to enhance treatment efficacy by simultaneously targeting two different antigens or epitopes. Bispecific monoclonal antibodies are a specialized class of engineered antibodies capable of binding to two distinct antigens or two separate epitopes on the same antigen. For instance, in March 2024, Roche Holding AG, a Switzerland-based pharmaceutical company, launched Vabysmo (faricimab-svoa), a bispecific monoclonal antibody for eye diseases, designed to treat neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). Vabysmo targets both VEGF-A and Angiopoietin-2 (Ang-2), improving vascular stability and reducing retinal fluid leakage. Its dual-target mechanism also allows extended dosing intervals of up to four months, significantly reducing the treatment burden for patients.

In February 2024, AbbVie Inc., a U.S.-based biopharmaceutical company, partnered with OSE Immunotherapeutics SA to develop a novel monoclonal antibody aimed at treating chronic and severe inflammation. This collaboration focuses on developing and commercializing OSE-230, a monoclonal antibody that activates ChemR23 to effectively resolve chronic inflammation and improve outcomes for patients with severe inflammatory diseases. OSE Immunotherapeutics SA is a France-based company dedicated to developing innovative immunotherapies, including monoclonal antibody therapeutics, for cancer and autoimmune diseases.

Major companies operating in the monoclonal antibody therapeutics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Daiichi Sankyo Company Limited, UCB S.A., Genmab A/S, ADC Therapeutics, Y‑mAbs Therapeutics.

North America was the largest region in the monoclonal antibody therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the monoclonal antibody therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the monoclonal antibody therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the monoclonal antibody therapeutics market by increasing the cost of imported raw materials, reagents, and biomanufacturing equipment. Segments such as antibody-drug conjugates, multi-specific antibodies, and fusion proteins are particularly impacted, with major effects in regions like North America and Asia-Pacific where imports are critical. The tariffs have led to higher production costs and potential delays in therapeutic development. On the positive side, tariffs encourage local manufacturing investments, innovation in biologics production, and development of cost-efficient domestic supply chains.

The monoclonal antibody therapeutics market research report is one of a series of new reports that provides monoclonal antibody therapeutics market statistics, including monoclonal antibody therapeutics industry global market size, regional shares, competitors with a monoclonal antibody therapeutics market share, detailed monoclonal antibody therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibody therapeutics industry. This monoclonal antibody therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Monoclonal antibody therapeutics are laboratory-engineered molecules designed to act as substitute antibodies that specifically target and bind to antigens, such as those present on cancer cells, pathogens, or components of the immune system. These therapies are developed to recognize and neutralize disease-causing agents or deliver drugs directly to targeted cells, making them an effective approach for treating various conditions, including cancers, autoimmune disorders, and infectious diseases.

The main product types in monoclonal antibody therapeutics include naked antibodies, fusion proteins, antibody fragments, conjugates, and multi-specific antibodies. Naked monoclonal antibodies are laboratory-produced proteins that are not linked to any other molecules, such as drugs or radioactive agents. These products are applied across multiple therapeutic areas, including autoimmune and inflammatory disorders, oncology, hematology, ophthalmology, and others, with applications in cancer, autoimmune diseases, infections, hematological disorders, and more. They are utilized by a wide range of end users, including hospitals, private clinics, and research institutions.

The monoclonal antibody therapeutics market consists of sales of murine monoclonal antibodies, humanized monoclonal antibodies, antibody-drug conjugates, anti-infective monoclonal antibodies, and immune effector cell engagers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.